Poor prognosis of urothelial carcinoma in patients presented with persistent paraneoplastic leukocytosis with anemia

Syah Mirsya Warli, Andy Andy¹, Fauriski Febrian Prapiska¹, Ginanda Putra Siregar¹, Bungaran Sihombing¹
Department of Urology, Faculty of Medicine, Universitas Sumatera Utara – Universitas Sumatera Utara Hospital, °Department of Surgery, Division of Urology, Faculty of Medicine, Universitas Sumatera Utara – Haji Adam Malik General Hospital, Medan, Indonesia

Abstract

Introduction: Paraneoplastic leukocytosis is a rare manifestation of urological cancer. This condition is well associated with the poor prognosis in other solid tumors. Anemia is the most common hematological manifestation of cancer, affecting 40%–64% of patients with cancer. This condition is also well associated with a poor prognosis. The goal of this research is to determine the clinical presentation and fate of individuals with urothelial carcinoma who have persistent paraneoplastic leukocytosis and anemia.

Methods: From January 2014 to December 2020, a retrospective cohort of patients with a histological result of urothelial carcinoma was collected. Data were extracted from a single National Cancer Center Hospital in Indonesia. Persistent leukocytosis is defined as a leukocyte count ≥ 20,000/mL on at least two occasions with a minimum interval of 30 days. Anemia is defined using the WHO definition of anemia. Urinalysis, chest X-ray, and other blood tests were performed to exclude other probable causes of leukocytosis.

Results: Thirteen of 123 patients screened presented with persistent paraneoplastic leukocytosis and anemia. All patients presented with bladder cancer, with two patients (15.4%) presented with a mixed histological urothelial carcinoma. During the trial, all of the patients died, with a median survival of 20 days after the beginning of paraneoplastic leukocytosis with anemia.

Conclusions: Persistent paraneoplastic leukocytosis and anemia in a patient with urothelial carcinoma are a rare condition that is associated to a poor prognosis and a lower median overall survival time.

Keywords: Anemia, bladder cancer, overall survival, paraneoplastic leukocytosis, urothelial carcinoma

INTRODUCTION

Paraneoplastic syndrome is a condition that may occur in all types of urological malignancies but rarely occurs in bladder cancer.[1,2] These syndromes can manifest as hematological abnormalities such as leukocytosis, thrombocytosis, and anemia.[1,2,3]

Paraneoplastic leukocytosis is a rare urological cancer symptom, appearing in 3% of patients with renal cell carcinoma and 1% of urothelial carcinoma.[4,5] This is more common in solid cancers, including lung cancer,[6,7] sarcoma,[7] and skin cancer.[7,8] The most prevalent hematological symptom of cancer is anemia, affecting...
40–64% of cancer patients. These symptoms have been associated with a poor prognosis in terms of outcomes and overall survival.

**METHODS**

From January 2014 to December 2020, a retrospective cohort of patients with a histological result of urothelial carcinoma from urological cancer in the renal, pelvic, ureter, and bladder was collected. Data were extracted from a single National Cancer Center Hospital in Indonesia. The ethics committee granted ethical permission before the start of the study.

Persistent leukocytosis in this study is defined as a leukocyte count ≥20,000/mL on at least two occasions with a minimum interval of 30 days. The WHO definition of anemia is used to describe anemia. Hemoglobin levels of less than 13.0 g/dL in a male and less than 12.0 g/dL in a female are considered anemia.

**RESULTS**

A total of 123 patients with urothelial carcinoma on histology were screened. Thirteen patients presented with persistent paraneoplastic leukocytosis and anemia. Patient characteristics are shown in Table 1. Two individuals had mixed histology with squamous involvement of the tumor, whereas the other had pure urothelial cell carcinoma histology.

Leukocytosis patients are dominantly neutrophil, with all patients having neutrophilia. All patients have anemia, one patient suffering mild anemia, six suffering moderate anemia, and six suffering severe anemia. Seven out of 13 patients also presented with thrombocytosis.

Table 2 depicts the disease course of the patients who took part in the research. During the trial, all of the patients died, with a median survival of 20 days after the beginning of paraneoplastic leukocytosis with anemia. All seven patients receiving chemoradiation were given gemcitabine-cisplatin regimen with radiotherapy for 35–36 times.

**DISCUSSION**

Patients with persistent paraneoplastic leukocytosis and anemia have a terrible prognosis, with a median survival of only 20 days, according to this study. Izard et al. found a similar finding in a study with persistent leukocytosis in urothelial carcinoma, with a median survival of 71 days after leukocytosis. All nine patients also presented with anemia and bladder as the majority of primary cancer sites in the study.

Increased production of granulocyte colony-stimulating factor (G-CSF) is related to persistent paraneoplastic leukocytosis. Myelopoiesis and the expansion of myeloid-derived suppressor cells and neutrophils are induced by G-CSF secretion. A high neutrophil level will restrict T-cell proliferation, causing a lower lymphocyte, subsequently causing a higher neutrophil-to-lymphocyte ratio (NLR) level. This condition is rare, although only several case reports have shown leukocytosis in a patient with bladder cancer due to a G-CSF-producing tumor. G-CSF has also been associated to tumor cell proliferation which is aggressive and has a poor clinical outcome. This condition can explain the cause of poor prognosis and short survival in this study.

As G-CSF promotes tumor progression and metastasis, tumors that produce it have a poor prognosis. A study by Kowanetz et al. shows that exposure to a high level of G-CSF for an extended time, simulating a G-CSF-producing tumor, enhances metastasis by mobilizing myeloid-derived suppressor cells from the bone marrow into distant organs, resulting in a protumorigenic milieu for metastasis. Anti-G-CSF also shows a significantly reduced risk of metastasis in mice.
High NLR levels on the study patients may also cause a poor prognosis. In a study by Viers et al., high NLR (≥2.7) in patients with urothelial cancer has an increased risk of mortality (Hazard Ratio = 1.03; P = 0.01). A high NLR is associated with a lower lymphocyte-associated immunological response and a higher neutrophil-dependent inflammatory reaction. A high level of neutrophils is related to a larger number of cytokines including interleukin-1, interleukin-6, and tumor necrosis factor, which promote vascular angiogenesis. A low lymphocyte level reflects a lower T-cell level, indicating a weak lymphocyte-mediated immune response to malignancy. All patients in this study have an NLR of higher than 15, which may cause a dysregulated immune response to cancer, causing rapid progression and poor prognosis.

Leukocyte level may be affected by the treatment given to the patient. Case reports also have shown that cystectomy will reduce leukocytosis level but will gradually increase after due to the natural progression of G-CSF-producing tumor. Chemoradiation received by the patient may cause neutropenia and lymphocytosis, subsequently reducing the NLR level. This condition did not occur in the patients as all patients had a high NLR level. The leukocytosis presenting is likely caused by urothelial cancer activity.

Anemia is also attributed to lower overall survival and cancer-specific survival. A meta-analysis by Luo et al. shows that anemia significantly lowers cancer-specific survival (HR = 2.21; 95% confidence interval [CI]: 1.83–2.65), recurrence-free survival (HR = 1.87; 95% CI: 1.59–2.20), and overall survival (HR = 2.04; 95% CI: 1.76–2.37). Hypoxia in the tumor microenvironment caused by anemia will induce genes such as p53, Vascular endothelial growth factor (VEGF), and Hypoxia-inducible factor 1 (HIF-1). A high VEGF level has been associated with bladder cancer progression and has been associated with a lower incidence of recurrence-free survival. HIF-1 from hypoxia can trigger angiogenesis that predicts poor prognosis in patients with urothelial carcinoma. Mutation in TP53, the gene encoding p53 tumor suppressor protein will cause dysfunction in the apoptotic potential and is significantly associated with relapse-free survival of urothelial carcinoma.

G-CSF affects erythropoiesis by inhibiting bone marrow erythropoiesis and enhancing splenic erythropoiesis. In a study by Papaldo et al., patients who received G-CSF had lower hemoglobin levels than others who did not. Patients who got more G-CSF injections had lower hemoglobin levels according to the study. Anemia on this study patients may be caused by G-CSF effect on erythropoiesis.

Cancer-induced anemia can be caused by multiple etiologies and is usually multifactorial. Anemia can arise from the treatment received by the patient. Postcystectomy and transurethral resection of bladder (TURBT) may cause blood loss and anemia. This condition, although is usually only short-term after the operation, Chemotherapy using gemcitabine-cisplatin and radiotherapy causes grade 3 or 4 anemia in 27%-40% of patients.

CONCLUSIONS

Persistent paraneoplastic leukocytosis and anemia in a patient with urothelial carcinoma are rare, and it is associated to a poor prognosis and a 20-day median overall survival.

FINANCIAL SUPPORT AND SPONSORSHIP

Nil.

CONFLICTS OF INTEREST

There are no conflicts of interest.

REFERENCES

1. Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A, et al. Paraneoplastic syndromes in patients with urological malignancies.
Urol Int 2009;83:1-11.

2. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. Rev Urol 2002;4:163-70.

3. Peloos LF, Gerber DE. Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838-54.

4. Ikuezowo SO, Ojewuyi OO, Osamvisie OA, Abafariti AA, Bioku MJ, Doherty AF. Paraneoplastic syndromes and oncological outcomes in renal cancer. Niger J Clin Pract 2019;22:1271-5.

5. Izard JP, Gore JL, Mostaghel EA, Wright JL, Yu EY. Persistent, unexplained leukocytosis is a paraneoplastic syndrome associated with a poor prognosis in patients with urothelial carcinoma. Clin Genitourin Cancer 2015;13:e253-8.

6. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ehbihara Y, Ohayashi K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92:2399-405.

7. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: A retrospective, single-institution study. Cancer 2009;115:3919-23.

8. Schmwind B, Christgen M, Hauschild A, Kordow R, Kalhoff H, Klomp HJ. Paraneoplastic leukocytosis reaction and rapid progression in a patient with malignant melanoma: Establishment of KT293, a novel G-CSF-secreting melanoma cell line. Cancer Biol Ther 2005;4:23-7.

9. Gaspar BL, Sharma P, Das R. Anemia in malignancies: Pathogenetic and diagnostic considerations. Hematology 2015;20:18-25.

10. Luo F, Wang YS, Su YH, Zhang ZH, Sun HH, Li J. Prognostic implications of preoperative anemia in urothelial carcinoma: A meta-analysis. PLoS One 2017;12:e0171701.

11. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Geneva: World Health Organization; 2011.

12. Tavakkoli M, Wilkins CR, Mones JV, Mauro MJ. A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer. Front Oncol 2019;9:295.

13. McMee SN, Gilbert R, Deamant FD, Reese JH. Poorly differentiated carcinoma of bladder producing granulocyte colony-stimulating factor and parathyroid hormone related protein. J Urol 2001;165:527-8.

14. Morinaga R, Kawahara T, Kuroda S, Inayama Y, Uemura H. Granulocyte colony-stimulating factor producing bladder cancer. Case Rep Oncol 2019;12:603-7.

15. Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, et al. Autoimmune growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1995;55:3438-43.

16. Ortiz ML, Lu I, Ramachandrani I, Gabrilovich DI. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res 2014;2:50-8.

17. Kovanetz M, Wu X, Lee J, Tan M, Hagenbeck T, Qu X, et al. Granulocyte colony-stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+granulocytes. Proc Natl Acad Sci U S A 2010;107:21248-55.

18. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 2014;66:1157-64.

19. Templeton AJ, Ace O, McNamara MG, Al-Maharak M, Vera-Badillo FE, Herrmann T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.

20. Ashamalla M, Wang W, Lewis C, Mian B, Mehdi S. Paraneoplastic leukemoid reaction – Poor prognostic marker in urothelial bladder carcinoma. J Community Support Oncol 2017;15:40-2.

21. Dukes W, Tierney LM Jr. Paraneoplastic leukemoid reaction as marker for transitional cell carcinoma recurrence. Urology 2009;73:9.e17-9.

22. Libsoni P, Fumagalli I, Brivio F, Rovelli F, Messina G, Di Fede G, et al. Cancer chemotherapy-induced lymphocytosis: A revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents 2006;20:29-35.

23. von der Maase H, Hansen SW, Roberts JT, Doglioni L, Oliver T, Moore MJ, et al. Gemicitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.

24. Kopparpu K, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, et al. Expression of VEGF and its receptors VEGFR1/ VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 2013;33:2381-90.

25. Theodoropoulos VE, Lazaris ACh, Sotras F, Gerzeli I, Tsoukala V, Ghiokonti I, et al. Hypoxia-inducible factor I alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-8.

26. Hodgson A, Xu B, Downes MR. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 2017;71:296-304.

27. Jing W, Guo X, Qin F, Li Y, Wang G, Bi Y, et al. G-CSF shifts erythropoiesis from bone marrow into spleen in the setting of systemic inflammation. Life Sci Alliance 2021;4:e202000737.

28. Papadko P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, et al. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol 2006;24:3048-55.

29. Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol 2020;145:102837.

30. Bansal A, Sankhwar S, Goel A, Kumar M, Purkait B, Aeron R. Grading of complications of transurethral resection of bladder tumor using Clavien-Dindo classification system. Indian J Urol 2016;32:232-7.

31. Bruins HM, Arends T, Pelkman M, Heijden AG, Witjes AJ. The prognostic value of pre-operative laboratory parameters in patients undergoing radical cystectomy for bladder cancer. J Urol 2013;189:e284.

32. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: A single-institution study. Cancer 2009;115:3919-23.

33. Ashamalla M, Wang W, Lewis C, Mian B, Mehdi S. Paraneoplastic leukemoid reaction – Poor prognostic marker in urothelial bladder carcinoma. J Community Support Oncol 2017;15:40-2.

34. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.